TG Therapeutics与FUJIFILM Diosynth Biotechnology签署制造供应协议

2024-11-05 00:06

TG Therapeutics (NASDAQ:TGTX) has signed a multi-year manufacturing supply agreement with FUJIFILM Diosynth Biotechnologies (OTCPK:FUJIY) for its multiple sclerosis drug.
Under the deal, FUJIFILM Diosynth will provide secondary US-based manufacturing supply for Briumvi, TG Therapeutics' FDA-approved drug for relapsing form of multiple sclerosis, at the company’s new biopharmaceutical manufacturing facility in North Carolina. The facility will be fully operational in 2025.
Shares of FUJIFILM Diosynth were up roughly 4%, while TG Therapeutics (NASDAQ:TGTX) lost 10% on Monday following quarterly results.
Source: Press Release

More on FUJIFILM Holdings